VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

Prior treatment

• Any prescription or over-the-counter medications intended for weight loss within 6 months of screening

Other illness

• History of or current clinically significant medical or psychiatric disorder that, in the opinion of the Investigator, does not support study participation
• Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)

Lab values

• Calcitonin ≥50 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)

Other

• Self-reported body weight change of 5% or more within 3 months of screening
• Current or past diagnosis of chronic pancreatitis
• Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening

• Age ≥18 years of age at the time of signing the informed consent.
• Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI \<50 kg/m2
  • Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
  • BMI calculated at the Screening visit will be used to determine eligibility.